Zepbound

News

Could Novo-Catalent deal face antitrust hurdles?

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities

News

Lilly launches telehealth option for obesity and other drugs

Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound, opening up a new direct-to-consumer (DTC) channel that could shake up

R&D

The race for obesity drug assets heats up

The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident.

News

Lilly to invest $2.5bn for obesity, diabetes drug production

Eli Lilly has followed Novo Nordisk in announcing a big investment in its manufacturing network, intended to meet anticipated strong future demand for diabetes and obesity

News

Lilly gets FDA okay for tirzepatide as obesity therapy

Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a

Could Novo-Catalent deal face antitrust hurdles?

Lilly launches telehealth option for obesity and other drugs

The race for obesity drug assets heats up

Lilly to invest $2.5bn for obesity, diabetes drug production

Lilly gets FDA okay for tirzepatide as obesity therapy

CDMOs: Their crucial role and how to select one, with Sigma ...

How to meet your physicians where they are online

Zepbound

Editor's Picks